北陆药业(300016.SZ)：碘美普尔化学原料药获批上市

Group 1 - The company, Beilu Pharmaceutical, announced that its subsidiary, Zhejiang Haichang Pharmaceutical Co., Ltd., received approval from the National Medical Products Administration for the marketing application of Iopamidol [1] - Iopamidol is a low-osmolar, non-ionic water-soluble contrast agent widely used in CT enhancement imaging and vascular imaging [1] - Compared to traditional high-osmolar contrast agents, Iopamidol places a lower burden on patients' kidneys and cardiovascular systems, making it particularly suitable for patients with renal impairment and those at high risk [1] Group 2 - Due to its excellent imaging effects and lower side effects, Iopamidol has become one of the preferred contrast agents in clinical settings [1]